Array BioPharma’s ARRY-797 Meets Primary Endpoint in Clinical Proof of Concept Trial in Osteoarthritis Patients Whose Pain is Poorly Controlled by NSAIDs Array BioPharma (NASDAQ: ARRY) today announced ...

Ambitious plans have been announced for a 15,000-hectare solar array near Tennant Creek in Australia’s Northern Territory. If built, the 10 GW solar farm would be the world’s biggest solar park and be ...

Array BioPharma Inc.'s p38-alpha kinase inhibitor, ARRY-797, hit its primary endpoint of reducing pain more than placebo in a Phase II proof-of-concept trial in 157 patients with knee pain due to ...